Molecular signatures of precancerous lesions: Changing paradigm of early detection
Tuesday, December 4, 2018
Main Scientific Session
•
MSS 07
•
1:30 PM
>
3:00 PM
•
Molecular signatures of precancerous lesions: Changing paradigm of early detection
•
Auditorium I
HPV screening has high sensitivity for CIN3 and cancer; however, because most HPV infections clear spontaneously, the test has relatively low specificity. Follow-up and clinical management of HPV positive women with a low risk of cervical cancer represents a large economic problem for national healthcare systems plus substantial emotional burdens for most women. As we move closer to a fully integrated molecular testing approach to human disease we must continue the search for more accurate biomarkers of disease. Evidence as to which triage test is best for HPV positive patients is lacking as is any clear signal to stop the search. We are still quite far from an ideal triage test. This session will explore the current state of the science in molecular methods to manage people infected by HPV.
1:30 PM
•
MSS 07-01
•
DNA methylation: clinical study results
>
A.
Attila
LORINCZ
1:45 PM
•
MSS 07-02
•
DNA methylation markers for the detection of CIN3 and cervical cancer in self-samples and urine
>
R.
Renske
STEENBERGEN
2:00 PM
•
MSS 07-03
•
Deep sequencing of HPV and human genome: what next?
>
L.
Lisa
MIRABELLO
2:15 PM
•
MSS 07-04
•
Oral gargle HPV 16 and EPB41L3 methylation: associations with oropharyngeal cancer tumor levels and detection
>
A.
Anna
GIULIANO
2:30 PM
•
MSS 07-05
•
Staging precancerous lesions using combined E6-E7 mRNA Quantification and Cell Cycle in Single Cells
>
B.
Bruce
PATTERSON
2:45 PM
•
MSS 07-06
•
Discussion
|